DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma

Leukemia. 2020 Mar;34(3):938-941. doi: 10.1038/s41375-019-0587-5. Epub 2019 Oct 8.

Authors

Priya Choudhry¹, Margarette C Mariano¹, Huimin Geng¹, Thomas G Martin 3rd², Jeffrey L Wolf², Sandy W Wong², Nina Shah², Arun P Wiita^{3

4}

Affiliations

¹ Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
² Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
³ Department of Laboratory Medicine, University of California, San Francisco, CA, USA. arun.wiita@ucsf.edu.
⁴ Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. arun.wiita@ucsf.edu.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

ADP-ribosyl Cyclase 1 / metabolism*
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cell Line, Tumor
DNA (Cytosine-5-)-Methyltransferase 1 / antagonists & inhibitors*
Drug Screening Assays, Antitumor
Drug Synergism
Gene Expression Regulation, Neoplastic*
Humans
Multiple Myeloma / drug therapy*
Multiple Myeloma / metabolism
Plasma Cells / metabolism

Substances

Antibodies, Monoclonal
daratumumab
DNA (Cytosine-5-)-Methyltransferase 1
DNMT1 protein, human
ADP-ribosyl Cyclase 1

Grants and funding